The Lung-MAP precision medicine trial in non-small cell lung cancer is approaching its 10-year anniversary. A decade of bringing the right treatment to the right patient at the right time. The master protocol's next evolution is coming soon: Lung-MAP 3.0! lung-map.org

#Lung MAP retreat at FNIH. NCI, FDA NCTN and investigators all here. Strategic planning ongoing. Here with friend & colleague Roy Herbst Lung-MAP NCI CTEP Clinical Research SWOG Cancer Research Network FDA Oncology Hossein Borghaei, DO Karen Reckamp, MD, MS

#Lung MAP. Umbrella master protocol driven by public-private partnership. Over 4,000 patients enrolled. 15 trials completed. Nothing else like it! Lung-MAP Hossein Borghaei, DO Karen Reckamp, MD, MS Jhanelle Gray MD GO2 for Lung Cancer

Basket trials. Umbrella trials. Platform trials. What's the difference? Here's a clear explanation from Andrew Ciupek of GO2 for Lung Cancer: go2.org/blog/new-clini…. Lung-MAP is an umbrella trial in #NSCLC #lungcancer . Patients are matched to targeted therapy by #biomarker testing.

S1900K, Lung-MAP's newest sub-study, was activated in December. For patients with MET exon 14 skipping #NSCLC . Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib.
clinicaltrials.gov/study/NCT06031…

Your patients with new MET amplification after #NSCLC has progressed on osimertinib may be eligible for Lung-MAP sub-study SWOG Cancer Research Network S1900G. MET amplification found by tissue assay at a CLIA-certified lab can be used. SWOG.org/clinical-trial… #lungcancer

Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial NCI CTEP Clinical Research Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network aacrjournals.org/clincancerres/…

Exciting Lung-MAP numbers to start 2024!
- 5,112 patients screened since 2014
- 1,163 patients enrolled to Lung-MAP sub-studies
- 815 institutions participating
- 18 sub-studies opened (a 19th very soon!)
- 15 genetic alterations targeted in sub-studies
lung-map.org

Compared to conventional trials in advanced #NSCLC , biomarker-driven Lung-MAP master protocol enrolled higher percentages of patients who are older, from rural or socioeconomically-deprived areas, or have Medicaid or no insurance. Analysis in JCO Precision Oncology
ascopubs.org/doi/abs/10.120…

.Lung-MAP is built on a unique public-private partnership w National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network #NCTN
Benefits:
- Shared costs & risks of testing therapies
- Drug combination collaborations between companies
- Size of network shortens trial timeframes
lung-map.org

Just activated! Lung-MAP's newest biomarker sub-study: S1900K. For patients with MET exon 14 skipping #NSCLC . Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib. SWOG.org/clinical-trial…

The Lung-MAP trial operates at more than 900 sites across the U.S., and ~50% of patients are enrolled from community-based sites. This means patients can get treatment near where they live. #NSCLC lungmap.org

Just activated! Lung-MAP's newest biomarker sub-study: S1900K. For patients with MET exon 14 skipping #NSCLC . Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib. SWOG.org/clinical-trial…

The Lung MAP master protocol is really “cooking” now. Another innovative Biomarker trial activated: S1900K in MET-mutated NSCLC. Over 5,000 patients enrolled in Lung MAP to date. Over 750 cIRB-approved sites. Nothing else like it in Oncology research. Lung-MAP Friends of Cancer Research

Just activated! Lung-MAP's newest biomarker sub-study: S1900K. For patients with MET exon 14 skipping #NSCLC . Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib.
clinicaltrials.gov/study/NCT06031…

The unique public-private partnership underlying the Lung-MAP precision medicine #NSCLC trial can serve as a model for #clinicalresearch that's more innovative & #inclusive . A special report in Clinical Cancer Research doi.org/10.1158/1078-0… National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network #lcsm

.Lung-MAP's unique public-private partnership can be a model for more rapid, innovative, & #inclusive #clinicalresearch . A special report in Clinical Cancer Research doi.org/10.1158/1078-0…
Read about it in our press release at
lung-map.org/10-years-maste… National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network #lcsm

Since its launch in 2014, Lung-MAP has worked to find the right #clinicaltrial for each patient, enrolling more than 1,100 patients to precision medicine studies testing new treatments for their #nonsmallcelllungcancer . #NSCLC #LungCancerAwarenessMonth lung-map.org

.Lung-MAP is built on a unique public-private partnership including National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network #NCTN
Partnership benefits:
- Shared costs & risks of testing therapies
- Drug combination collaborations between companies
- Size of network shortens trial timeframes

An JCO Precision Oncology editorial commenting on Lung-MAP paper by @riharv et al:
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) ascopubs.org/doi/10.1200/PO… Foundation for the National Institutes of Health SWOG Cancer Research Network Friends of Cancer Research NCI CTEP Clinical Research Hossein Borghaei, DO Karen Reckamp, MD, MS